PI3K/mTOR and topoisomerase inhibitors with potential activity against SARS-CoV-2 infection
White, J. R.; Foote, M. B.; Jee, J.; Argiles, G.; Wan, J. C. M.; Diaz, L. A.
Show abstract
There is an urgent need to identify therapies to prevent and treat SARS-CoV-2 infection. We performed a statistical evaluation of in vitro gene expression profiles reflecting exposure to 1,835 drugs, and found topoisomerase inhibitors and PI3K/mTOR pathway inhibitors among the strongest candidates for reduced expression of ACE2, a host gene associated with SARS-CoV-2 infection. Retrospective clinical data suggest that patients on these agents may be less likely to test positive for SARS-CoV-2.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Safety and Efficacy of Oral administrated Cepharanthine in Non-hospitalized, asymptomatic or mild COVID-19 patients: A Double-blind, Randomized, Placebo-controlled Trial 92%
- High rate of major drug-drug interactions of lopinavir-ritonavir for COVID-19 treatment 92%
- Probenecid Inhibits SARS-CoV-2 Replication In Vivo and In Vitro 92%
Similar papers in this journal
- Safety and effectiveness of RBD-specific polyclonal equine F(ab′)2 fragments for the treatment of hospitalized patients with severe Covid-19 disease: a retrospective cohort study 92%
- Detailed disease progression of 213 patients hospitalized with Covid-19 in the Czech Republic: An exploratory analysis 91%
- Combining explainable machine learning, demographic and multi-omic data to identify precision medicine strategies for inflammatory bowel disease 91%
Similar papers in this journal
- Evaluation of the current therapeutic approaches for COVID-19: a meta-analysis 93%
- Atovaquone for Treatment of COVID-19: A Prospective Randomized, Double-Blind, Placebo-Controlled Clinical Trial 91%
- Reported Drug Spectrum and Disproportionality Signals for Malignant Neoplasm Progression in FAERS: A Real-World Pharmacovigilance Study 91%
Similar papers in this journal
- Efficacy and safety of nitazoxanide combined with ritonavir-boosted atazanavir for the treatment of mild to moderate COVID-19 92%
- Current Understanding of COVID-19 Clinical Course and Investigational Treatments 91%
- The Association Between Alpha-1 Adrenergic Receptor Antagonists and In-Hospital Mortality from COVID-19 90%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.